

ALLINA HEALTH LABORATORY

To: Allina Health Laboratory outreach clients
From: Allina Health Laboratory outreach services
Date: June 17, 2024
Re: Test changes

Effective June 18, 2024, the following test changes will occur:

Anaplasma/Ehrlichia smear (453/LAB453) will be discontinued at Allina Health Laboratory. Manual smear examination has a low sensitivity and is labor intensive. Providers seeking testing for Anaplasma/Ehrlichia should order Anaplasma/Ehrlichia detection, PCR (13525/LAB13525) performed at LabCorp. Refer to the Allina Health Laboratory [Tick-born Disease Algorithm](#) for additional available testing.

Soluble Transferrin Receptor (6330/LAB6330) will be discontinued at Allina Health Laboratory. Testing will be referred to LabCorp and a new orderable code will be available, 14576/LAB14576. There will be a change in reported units from mg/L to nmol/L. Be aware of the changes in reporting and the potential to misinterpret seemingly incongruous values.

Fragile X Syndrome, PCR with reflex to Southern Blot has been discontinued by LabCorp. The replacement test is Fragile X Syndrome, Carrier and a new orderable code will be available, 15269/LAB15269.

Allina Health Laboratory is offering a new test for high-sensitivity residual disease monitoring for acute myeloid leukemia (AML), Acute Myeloid Leukemia Measurable Residual Disease (AML MRD) (12420/LAB12420) by multiparameter flow cytometry. The assay achieves a sensitivity of 0.01%, and is designed to characterize and enumerate residual leukemic blasts, stem cells, and other hematopoietic precursors in bone marrow samples of patients undergoing treatment for AML. The AML MRD panel is comprised of four tubes, each providing focused analysis of a specific cell lineage: Neutrophilic (M1), Monocytic (M2), Erythroid/Aberrant lymphoid markers (M3), and Stem Cell (M4) with a total of 26 billable markers.

The current Residual Acute Myeloid Leukemia (12420/LAB12420) will be renamed to Qualitative Myeloblast Analysis. It is a panel comprised of tubes M1, M2, and M4, and can be ordered in a diagnostic setting for qualitative phenotypic assessment of myeloid precursors and stem cells in patients being assessed for possible myeloid neoplasm.

Please refer to the Allina Health test catalog for specimen collection and processing instructions.

QUESTIONS: Contact your Allina Health Laboratory account representative, or our Client Services department
Telephone: 612-863-4678 • 800-281-4379 Email: centrallabclientservices@allina.com
www.allinahealth.org/allinahealthlaboratory